1
|
Tastekin [13]
|
24/male
|
Rt lobe
|
6 × 6 × 4 cm
|
III LV
|
Resection of liver tumor
|
Resection of tumor thrombus
|
18 mo
|
Dead
|
2
|
Ehrich [14]
|
62/male
|
Lt lobe
|
ND
|
III RA
|
Resection of tumor thrombus
|
Radiation therapy
|
12 mo
|
Alive
|
3
|
Li [15]
|
66/male
|
Rt lobe
|
12 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
6 mo
|
Dead
|
4
|
Oncale [16]
|
76/male
|
Rt lobe
|
12 × 8 cm
|
II
|
Sorafenib
|
No
|
14 mo
|
Dead
|
5
|
Miller [17]
|
30/male
|
Extensive involvement
|
ND
|
III RA
|
Resection of tumor thrombus
|
Radiation therapy and immunotherapy
|
6 mo
|
Alive
|
6
|
Chang [4]
|
57/male
|
RAS
|
9.6 × 8.6 cm
|
III RA
|
Thalidomide
|
No
|
12 mo
|
Alive
|
76/male
|
MHV
|
2 cm
|
III RA
|
TACE
|
Thalidomide
|
18 mo
|
Dead
|
67/female
|
Seg5, Seg8
|
7 cm
|
III RA
|
Thalidomide
|
No
|
5 mo
|
Alive
|
7
|
Inoue [39]
|
67/male
|
Seg2, Seg3
|
1.2 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
27 mo
|
Alive
|
8
|
Luo [18]
|
35/male
|
Lt lobe, RAS
|
ND
|
III RA
|
Percutaneous microwave ablation
|
No
|
6 mo
|
Dead
|
9
|
Goto [19]
|
36/female
|
Rt lobe
|
ND
|
III RA
|
Resection of tumor thrombus
|
TACE
|
7 mo
|
Dead
|
10
|
Kawakam [20]
|
66/female
|
Extensive involvement
|
ND
|
III RA
|
Symptomatic treatment
|
TACE
|
5 mo
|
Dead
|
11
|
Sun [21]
|
45/male
|
Lt lobe
|
ND
|
III RA
|
TACE
|
No
|
46 mo
|
Alive
|
12
|
Georgen [22]
|
22/female
|
Seg7
|
6 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
30 mo
|
Dead
|
13
|
Noguchi [23]
|
66/male
|
Rt lobe
|
2 cm
|
III RA
|
Symptomatic treatment
|
No
|
1 mo
|
Dead
|
14
|
Ohta [43]
|
60/male
|
Rt lobe
|
ND
|
III RA
|
Resection of liver tumor and tumor thrombus
|
Sorafenib
|
10 mo
|
Alive
|
15
|
Sengodan [24]
|
44/male
|
Rt lobe
|
5.6 × 7.6 × 5.5 cm
|
III RA
|
Sorafenib
|
Anticoagulation
|
2 mo
|
Dead
|
16
|
Hayashida [25]
|
72/male
|
Lt lobe
|
ND
|
III RA
|
Resection of tumor thrombus
|
TACE
|
6 mo
|
Dead
|
17
|
Sawada [26]
|
62/male
|
Extensive involvement
|
ND
|
III RA
|
Glypican-3-derived peptide vaccination
|
TACE, sorafenib
|
56 d
|
Dead
|
18
|
Shivathirthan [40]
|
71/male
|
Seg 7
|
ND
|
III RA
|
Resection of liver tumor and tumor thrombus
|
TACE
|
ND
|
ND
|
19
|
Miyazawa [27]
|
55/male
|
RAS
|
7 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
12 mo
|
Alive
|
20
|
Li [28]
|
64/male
|
Seg 6, Seg7
|
5.3 × 3.6 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
6 mo
|
Dead
|
21
|
Wu [42]
|
42/male
|
RAS
|
1.5 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
TACE
|
14 mo
|
Dead
|
22
|
Giuliani [29]
|
47/male
|
Lt lobe
|
Mutiple
|
III RA
|
External beam radiation therapy
|
No
|
7 mo
|
Dead
|
23
|
Leo [30]
|
45/male
|
Lt lobe
|
ND
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
6 mo
|
Alive
|
24
|
Florman [3]
|
55/male
|
Lt lobe
|
18 × 3 × 7 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
3 mo
|
Alive
|
25
|
Sung [31]
|
71/male
|
Rt lobe
|
ND
|
III RA
|
Resection of tumor thrombus
|
Sorafenib
|
7 mo
|
Alive
|
26
|
Ohwada [32]
|
77/female
|
LLS
|
10 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
3 mo
|
Alive
|
27
|
Lin [33]
|
57/male
|
Rt lobe
|
4.5 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
3 D
|
Dead
|
28
|
Yogita [34]
|
61/male
|
LMS
|
3 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
56 mo
|
Dead
|
29
|
Masaki [35]
|
47/male
|
Seg 8
|
3 × 2.5 × 2 cm
|
III RA
|
Resection of tumor thrombus
|
TAE and radiation therapy
|
8 mo
|
Dead
|
48/male
|
Seg 7
|
ND
|
III LP
|
Resection of tumor thrombus in the IVC and LPA
|
TAE
|
29 D
|
Dead
|
30
|
Kashima [20]
|
66/male
|
Rt lobe
|
10 × 7 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
TACE
|
59 mo
|
Alive
|
31
|
Fujisaki [36]
|
38/female
|
LLS
|
8 × 8 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
No
|
15 mo
|
Alive
|
32
|
Dazai [37]
|
42/male
|
Rt lobe
|
ND
|
III RA
|
TACE
|
No
|
7 mo
|
Dead
|
33
|
Kurahashi [38]
|
81/male
|
Rt lobe
|
11.5 cm
|
III RA
|
Resection of liver tumor and tumor thrombus
|
Oncologic treatment
|
72 mo
|
Alive
|